eli lilly and company retatrutide Who got retatrutide; Pfizer lung cancer trial: The Readout Lilly's Retatrutide Continues To Show

Retatrutide differs from other weight loss medicines partly because the glucagon receptor it activates is thought to increase energy expenditure and promote fat burning in addition to the appetite-suppressing effects of GLP-1 and GIP

Others may need a slower titration, a dose adjustment, or a discussion about long-term medication strategy

The sharpest contraction appears in categories associated with high sugar and high caloric density snack foods, confectionery and certain fastfood segments

In summary, GLP-/GIP dual agonists have shown superior potential over GLP-1 in improving lipid metabolism

Copyright 2026 WBUR

GLP-1 medications present a unique calcium concern